Page loading, please wait...
Antibiotics and antimicrobial therapy
Hello, guest! :: Today: Monday, July 22, 2019 Russian page Russian 
 Main page :: IAC :: ISPR :: SCMAR :: IACMAC :: CMAC
Site navigation


Clinical Microbiology and Antimicrobial Chemotherapy - Official IACMAC Journal
Conferences, Seminars and Workshops

IACMAC activity plan for 2018-2019

  • Eurasian Congress on Antimicrobial Therapy and Clinical Microbiology (October 17–18, 2019, Ufa)
  • Certification workshop of professional education on specialty “Bacteriology” (October 21 – November 22, 2019, Smolensk)

Online course “Antimicrobial Stewardship: Managing Antibiotic Resistance”

You are invited to participate in Massive Open Online Course (MOOC) in Russian. This educational course was developed by Dundee University, the British Society for Antimicrobial Chemotherapy (BSAC) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC).

IACMAC Educational Program

The National educational program “Diagnostics, treatment and prevention of infectious diseases caused by multidrug resistant microorganisms”

Nosocomial infectious diseases (2 session)

  • 21.09.2019 — Europe Park-Hotel, 292B, Volchanskaya, Belgorod
  • 05.10.2019 — DoubleTree by Hilton Tyumen Hotel, 46, Ordzhonikidze, Tumen

Community-acquired infectious diseases (3 session)

  • 14.09.2019 — Amaks Yubileynaya Hotel, 6, Yubileynaya, Tolyatti
  • 05.10.2019 — Piter Inn, 1, Gagarin Square, Petrozavodsk

Dear Colleagues! Due to certain technical issues and obstacles the list of cities participating in the National educational program “Diagnostics, treatment and prevention of infectious diseases caused by multidrug resistant microorganisms. Nosocomial infectious diseases” was shortened.


Dear colleagues! We encourage to take part in multicenter prospective microbiological study of the antimicrobial resistance of community-acquired pathogens: S. pneumoniae, H. influenzae and S. pyogenes (PeGAS study).

Since 2015 IAC and IACMAC have conducted multicenter study aimed to evaluate the prevalence of mutation resistance to macrolide antibiotic in Mycoplasma pneumonia and Mycoplasma genitalium.

Website News

European Committee on Antimicrobial Susceptibility Testing (EUCAST) has amended the clinical classification of susceptibility (categories S,I and R): currently the clinical evaluation of susceptibility is connected with drug exposure in the nidus of infection.

The occupational standard on specialty "Medical microbiology" from the Ministry of Healthcare of the Russian Federation is posted on IACMAC website.

Clinical Microbiology and Antimicrobial Chemotherapy vol. 20, №3 is posted on the website.

Clinical guidelines on diagnostics and treatment of community-acquired pneumonia in adults.

The Russian Respiratory Society (RRC) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC) have published for discussion the clinical guidelines on diagnostics and treatment of community-acquired pneumonia in adults.

Clinical guidelines “Mucoviscidosis: microbiological diagnostics of chronic respiratory infection”

Clinical guidelines on antimicrobial susceptibility testing, approved at the IACMAC extended session in Moscow are posted on the website.

Clinical guidelines on isolation, identification and antimicrobial susceptibility of Helicobacter pylori are added.

New Articles
Site News

FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia

The U.S. Food and Drug Administration today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections.
Jun 13, 2019 - 11:20
Read more... :: Reads: 394
Site News

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

To compare the risk of serious infection associated with biologic and nonbiologic systemic medications in patients with psoriasis.
Jun 03, 2019 - 10:05
Read more... :: Reads: 521
Site News

Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria

This study uses in vitro assays and a mouse model to investigate antibacterial properties of ticagrelor to follow up findings from 2 clinical trials that showed patients taking ticagrelor for cardiovascular disease had a lower risk of infection-related death and improved lung function compared with patients treated with clopidogrel.
Jun 01, 2019 - 10:10
Read more... :: Reads: 529
Site News

Prophylactic antibiotics for the prevention of infection following operative vaginal delivery (ANODE): study protocol for a randomised controlled trial

Risk factors for maternal infection are clearly recognised, including caesarean section and operative vaginal birth. Antibiotic prophylaxis at caesarean section is widely recommended because there is clear systematic review evidence that it reduces incidence of maternal infection. Current WHO guidelines do not recommend routine antibiotic prophylaxis for women undergoing operative vaginal birth because of insufficient evidence of effectiveness. We aimed to investigate whether antibiotic prophylaxis prevented maternal infection after operative vaginal birth.
May 31, 2019 - 11:05
Read more... :: Reads: 531
Site News

Once-Daily Plazomicin for Complicated Urinary Tract Infections

The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae.
May 30, 2019 - 10:15
Read more... :: Reads: 531
Site News

Osteoarticular manifestations of human brucellosis: A review

Brucellosis is a common global zoonotic disease, which is responsible for a range of clinical manifestations. Fever, sweating and musculoskeletal pains are observed in most patients. The most frequent complication of brucellosis is osteoarticular involvement, with 10% to 85% of patients affected.
May 29, 2019 - 12:15
Read more... :: Reads: 531
Site News

Effectiveness of honey dressing in the treatment of diabetic foot ulcers: A systematic review and meta-analysis

Honey dressing has been applied in the treatment of diabetic foot ulcers (DFUs). However, there is a lack of research showing ample evidence that honey dressing is more effective in the treatment of DFUs than other dressings. This study aimed to examine the effects of honey dressing on wound-healing process for DFUs.
Mar 20, 2019 - 10:15
Read more... :: Reads: 726
Site News

Eravacycline: A review in complicated intra-abdominal infections

Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms.
Mar 18, 2019 - 10:15
Read more... :: Reads: 706
Site News

Use and safety of azithromycin in neonates: a systematic review

Azithromycin significantly reduces the risk of BPD in preterm neonates. The relationship between azithromycin and IHPS requires further investigation.
Mar 06, 2019 - 10:20
Read more... :: Reads: 730
Site News

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

Addition of S. boulardii to sequential therapy improved H. pylori eradication rate and reduced the incidence of treatment-associated AEs in Moroccan patients with H. pylori infection.
Mar 05, 2019 - 10:15
Read more... :: Reads: 674
Next »

Institute of Antimicrobial Chemotherapy (IAC) Scientific Center of Monitoring Antimicrobial Resistance The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy Department of Clinical Pharmacology
© 2000-2019 IAC SSMA